Table 1.

Patient and disease characteristics

ParameterEmibetuzumab monotherapy (Part A)Emibetuzumab + erlotinib (Part A2)
Number of patientsN = 23N = 14
Age, mean (SD)61.6 (10.6)68.3 (9.6)
Sex, n (%)
 Female10 (43.5)8 (57.1)
 Male13 (56.5)6 (42.9)
Race
 Caucasian20 (87.0)13 (92.9)
 African descent3 (13.0)1 (7.1)
Weight (kg), mean (SD)73.1 (18.8)72.0 (17.1)
ECOG performance status, n (%)
 06 (26.1)0 (0.0)
 117 (73.9)12 (85.7)
 20 (0.0)2 (14.3)
Type of cancer, n (%)
 Colorectal9 (39.1)0 (0.0)
 NSCLC4 (17.4)14 (100.0)
 Ovarian2 (8.7)0 (0.0)
 Othera8 (34.8)0 (0.0)
Prior therapies, n (%)
 Prior systemic therapy*23 (100)14 (100)
 Prior radiotherapy11 (47.8)9 (64.3)
 No prior therapy reported0 (0)0 (0)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; N, population size; n, number of patients in group.

  • aCancer types included adrenal cortical adenocarcinoma, breast, gastric, head and neck, hepatocellular, malignant mesothelioma, papillary cell carcinoma, and papillary urothelial (each n = 1).

  • *Patients had a wide range of treatments.